Currently, only three predictive biomarkers have been approved by the US FDA for ICI therapy in cancers, namely programmed death-ligand 1 (PD-L1), microsatellite instability (MSI) or defective mismatch repair (dMMR), and tumor mutational burden (TMB). The gene discussed is CD274; the disease is neoplasm.